Lakefront Biotherapeutics (LKFT) Invested Capital (2014 - 2025)

Lakefront Biotherapeutics (LKFT) has 12 years of Invested Capital data on file, last reported at $3.8 billion in Q4 2025.

• Invested Capital for Q4 2025 came in at $3.8 billion, up 19.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.8 billion (up 19.19% YoY), and the FY2025 annual result was $3.8 billion, up 19.19% from the prior year.
• Invested Capital improved to $3.8 billion in Q4 2025 per LKFT's latest filing, from $3.2 billion in the prior quarter.
• Over five years, Invested Capital peaked at $3.8 billion in Q4 2025 and troughed at $404635.2 in Q2 2021.
• A 5-year average of $2.3 billion and a median of $3.1 billion in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2021 and 2025: Invested Capital plunged 98.66% in 2021, then grew 19.19% in 2025.
• A 5-year view of Invested Capital shows it stood at $3.2 billion in 2021, then fell by 14.37% to $2.7 billion in 2022, then climbed by 16.18% to $3.1 billion in 2023, then advanced by 2.02% to $3.2 billion in 2024, then increased by 19.19% to $3.8 billion in 2025.
• Business Quant data shows LKFT's Invested Capital at $3.8 billion in Q4 2025, $3.2 billion in Q4 2024, and $3.1 billion in Q4 2023.